Evidence map›Paper›PMID 32034008›Full record

SynthesisHeart (British Cardiac Society)2020

P2Y

Florentino Lupercio, Shaun Giancaterino, Pedro Arturo Villablanca, Frederick Han, Kurt Hoffmayer, Gordon Ho, Farshad Raissi, David Krummen, Ulrika Birgersdotter-Green, Gregory Feld and 3 more

Open access · greenAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Heart (British Cardiac Society), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Apixaban and clopidogrel in a fixed-dose combination: Formulation and in vitro evaluation.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024
    Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Florentino Lupercio *Division of Cardiovascular Medicine, Sulpizio Cardiovascular Center, University of California, San Diego, La Jolla, California, USA.
Shaun Giancaterino *Division of Cardiovascular Medicine, Sulpizio Cardiovascular Center, University of California, San Diego, La Jolla, California, USA.ORCID 0000-0002-5588-0522
Pedro Arturo VillablancaDivision of Cardiology, Henry Ford Heart and Vascular Institute, Detroit, Michigan, USA.
Frederick HanDivision of Cardiovascular Medicine, Sulpizio Cardiovascular Center, University of California, San Diego, La Jolla, California, USA.
Kurt HoffmayerDivision of Cardiovascular Medicine, Sulpizio Cardiovascular Center, University of California, San Diego, La Jolla, California, USA.
Gordon HoDivision of Cardiovascular Medicine, Sulpizio Cardiovascular Center, University of California, San Diego, La Jolla, California, USA.
Farshad RaissiDivision of Cardiovascular Medicine, Sulpizio Cardiovascular Center, University of California, San Diego, La Jolla, California, USA.
David KrummenDivision of Cardiovascular Medicine, Sulpizio Cardiovascular Center, University of California, San Diego, La Jolla, California, USA.
Ulrika Birgersdotter-GreenDivision of Cardiovascular Medicine, Sulpizio Cardiovascular Center, University of California, San Diego, La Jolla, California, USA.
Gregory FeldDivision of Cardiovascular Medicine, Sulpizio Cardiovascular Center, University of California, San Diego, La Jolla, California, USA.
Ryan ReevesDivision of Cardiovascular Medicine, Sulpizio Cardiovascular Center, University of California, San Diego, La Jolla, California, USA.
Ehtisham MahmudDivision of Cardiovascular Medicine, Sulpizio Cardiovascular Center, University of California, San Diego, La Jolla, California, USA.
Jonathan C HsuDivision of Cardiovascular Medicine, Sulpizio Cardiovascular Center, University of California, San Diego, La Jolla, California, USA jonathan.hsu@ucsd.edu.
University of California San Diego · US

Funding

American Heart Association-American Stroke Association 19CDA34760021
6 · The paper itself

Abstract

objectiveThis study aimed to compare the safety and efficacy of third-generation P2Y

methodsWe performed a systematic review including both prospective and retrospective studies that compared dual and triple antithrombotic regimens for bleeding and major adverse cardiac events (MACE) in patients with AF undergoing PCI. We analysed rates of bleeding and MACE by P2Y

resultsA total of 22 014 patients were analysed from the seven studies included. Among patients treated with both OAC and P2Y

conclusionBased on this meta-analysis, the use of clopidogrel is associated with a lower rate of bleeding compared with ticagrelor or prasugrel in patients with AF on OAC undergoing PCI.

Indexed as

Percutaneous Coronary InterventionAdministration, OralAnticoagulantsAtrial FibrillationCoronary Artery DiseaseDrug Therapy, CombinationHumansPurinergic P2Y Receptor AntagonistsThrombosisAnticoagulantsPurinergic P2Y Receptor Antagonistsantiplateletatrial fibrillationoral anticoagulationP2Y12 inhibitorpercutaneous coronary intervention

Identifiers

PMID32034008
PMCPMC7265981
OpenAlexW3004623734

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.